PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours
Open Access
- 1 August 2018
- journal article
- research article
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 12, 16-20
Abstract
No abstract availableKeywords
Funding Information
- The Royal Marsden
- The Institute of Cancer Research
- ECMC Combinations Alliance
- The Rosetrees Trust
- National Institute for Health Research
- Biomedical Research Centre
This publication has 14 references indexed in Scilit:
- Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric MicronucleiMolecular Cancer Therapeutics, 2017
- Human Papillomavirus–Negative Pharyngeal CancerJournal of Clinical Oncology, 2015
- Selective Targeting of the G2/M Cell Cycle Checkpoint to Improve the Therapeutic Index of RadiotherapyClinical Oncology, 2014
- Radiotherapy Demand and Activity in England 2006–2020Clinical Oncology, 2013
- Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776Clinical Cancer Research, 2013
- Abstract 2348: Discovery of AZD6738, a potent and selective inhibitor with the potential to test the clinical efficacy of ATR kinase inhibition in cancer patients.Cancer Research, 2013
- Targeted Radiosensitization by the Chk1 Inhibitor SAR-020106International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapyCancer Biology & Therapy, 2012
- Targeting radiation-resistant hypoxic tumour cells through ATR inhibitionBritish Journal of Cancer, 2012
- Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2 Checkpoint and Inhibition of Homologous Recombinational DNA RepairCancer Research, 2010